News|Videos|November 20, 2026

Gray Areas: Has Traditional Immunotherapy Lost Its Place in Myasthenia Gravis?

Fact checked by: Kelly King

At the 2026 AANEM Annual Meeting, Michael Hehir, MD, makes the case that traditional immunotherapy still belongs at the center of long-term myasthenia gravis management, citing outcome data, patient burden, and the costs that often go undiscussed.

Myasthenia gravis (MG) has entered a new era of treatment options. Over the past several years, a wave of novel therapies, including C5 complement inhibitors and FcRn inhibitors, have earned FDA approvals and generated considerable excitement across the neuromuscular community. For patients who previously struggled to respond to conventional agents, these newer drugs have offered meaningful relief, and for many clinicians, the question has quietly shifted from whether to use newer therapies to when and for whom.

At the 2026 AANEM Annual Meeting, Michael Hehir, MD, professor of neuromuscular medicine at the University of Vermont College of Medicine in Burlington, Vermont, took the stage to argue the other side of that debate. His position: traditional immunotherapies, including mycophenolate mofetil, azathioprine, and rituximab, should remain the foundation of long-term maintenance treatment in myasthenia gravis.

It is a stance rooted in the depth of data behind these agents, which demonstrate rates of minimal manifestation status as high as 60 to 80%, outcomes that newer monotherapies have not yet matched. He also raised a point that often goes unspoken in clinical discussions: the stark difference in cost, with traditional therapies running a few hundred to a few thousand dollars per year, compared to $300,000 to $500,000 annually for some of the newer generation options.

On this episode of Gray Areas, Hehir breaks down what the evidence actually supports for long-term MG management, how he guides the treatment conversation with patients in his own clinic, and where he believes research must go next to help the field move from debate to data-driven consensus.

Timeline

The Myth: [1:00 - 2:52]

New generation therapies in MG have generated real excitement, particularly for refractory patients who did not respond to conventional options. Hehir acknowledges the wins these agents have delivered, while beginning to lay out why he believes traditional immunotherapy still has a central role to play.

What the Evidence Shows: [2:52 - 3:54]

Hehir walks through the data supporting traditional oral immunotherapies like mycophenolate and azathioprine as long-term maintenance options, noting that rates of minimal manifestation status can reach 60 to 80 percent with these agents, results that newer monotherapies have yet to replicate. He also discusses the value of layering quicker-onset therapies, such as IVIg or FcRn inhibitors, while waiting for traditional agents to reach their full effect.

Clinical Implications: [3:54 - 6:02]

For clinicians managing MG day to day, Hehir outlines the factors that should guide maintenance conversations: burden of therapy, patient lifestyle, side effect profile, efficacy, and cost. He speaks candidly about the financial reality of newer agents, estimating that if just 10 percent of MG patients were maintained on a newer therapy long term, that would amount to roughly $5 billion annually for approximately 10,000 people.

What We Still Don't Know: [6:03 - 7:31]

Hehir identifies two major gaps holding the field back: the absence of a head-to-head comparative effectiveness trial pitting traditional against newer therapies, and the lack of validated biomarkers that could help predict which patients are most likely to respond to a given agent. His team is actively working on a proposal to address the former.


Related to this article